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Xenografts in septic vascular
surgery
Xenogeneic materials are increas-
ingly being applied in arterial
reconstruction procedures in vascu-
lar surgical routine. Their availability,
good handling and high resistance
to infection have led to these grafts
also being used for procedures in the
septic surgery environment. Initial
results from application studies are
now available.
Due to its high resistance to infection and
excellent long-term stability, autologous
vascular grafts nowadays represent the
best method in septic vascular surgery;
however, should this option be unavail-
able, alloplastic materials lag far behind
despite various modiﬁcations (e.g. sil-
ver, Triclosan) to the vein in terms of
the characteristics mentioned. Further-
more, the removal of (in particular deep)
veins causes additional access morbid-
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Fig. 18A tube is produced from a bovine patch over an 8mmdiameter
cylinder. Non-absorbable sutures are used. In caseswhere it is not possible
to accurately determine the required graft length, the suture is left uncom-
pleted approximately 1–2 cm from the endof the patch to be completed in
situ
Fig. 28 Partial replacement of a graft shunt in the upper armwith a bovine
tube due to an infected aneurysm
ity and signiﬁcantly prolongs procedu-
ral times. The use of biological graft
materials was restricted for a long time
due to the limited long-term function,
degeneration and aneurysm formation,
as well as high occlusion rates (partic-
ularly in peripheral areas). In view of
the age and comorbidity-related reduc-
tion in life expectancy among patients
requiring vascular surgery due to under-
lying infectious diseases or septic com-
plications, allograftshave come toplay an
important role in clinical routine, partic-
ularly in the case of intracavitary infec-
tions; however, since the revised version
of the German Tissue Act (Gewebege-
setz) came into eﬀect in 2009, the pro-
curement, processing, storage and trans-
plantation of human tissue are subject to
strict requirements, signiﬁcantly limiting
the availability of these materials. Xeno-
geneicgraftsnowholdaﬁrmplace inelec-
tive vascular surgical practice. The term
(Greek ξένoς, xénos, stranger) refers to
materials of non-human biological ori-
gin. Originally, the shortage of suitable
human donor organs led to attempts to
transplant non-human organs but acute
rejectionprocesses posed the greatest ob-
stacle. These mechanisms can now be
even further suppressed in pigs as donor
animals for human heart transplants by
breeding knockout lines for superﬁcial
antigens and the use of immunoadsorp-
tion techniques. Despite this progress,
xenotransplantation of living tissue or
functional organs has not yet reached
the clinical routine. Denatured xeno-
geneic vessels are not suitable for vas-
cular replacement due to their tendency
to degenerate and high thrombogenic-
ity. Human Allo-Grafts used in vascular
surgery are rendered cell-free and hence
epitope-free, bymeansof specialprocess-
ing. Thus, they induce no speciﬁc im-
mune response. This article discusses the
role that the various currently available
grafts can play in the setting of infection.
Gefässchirurgie Suppl 2 · 2016 S55
Leitthema
Fig. 38Omniﬂow composite bypass and vein to reconstruct an infected
femorocrural bypass to theposterior tibial artery.The composite anastomo-
sis is constructed as an oblique end to end anastomosis
Fig. 48An aortobifemoral composite graft is produced using a pericardial
tube and twoOmniﬂow II grafts (8mmdiameter)
Pericardial patches
The industry oﬀers patches originating
from a variety of species. Bovine and
porcine pericardial patches are those
most commonly used. They diﬀer in
terms of biomechanical properties, in
particular material thickness and tensile
strength. At our hospital, the bovine
patch is used as the standard patch for
elective procedures in all vascular areas
excluding the popliteocrural region. The
porcine patch is better suited for this
region due to its low material thickness.
Bovine pericardial patches have several
advantages compared with alloplastic
materials; however, these advantages are
based purely on experience and have not
yet been documented in an evidence-
based manner. They are nevertheless
characterized by good handling, high
material strength and a low tendency
to bleeding at the suture line. Their
biocompatibility is signiﬁcantly higher
than that of alloplastic materials, a fact
attributed to the collagenic ﬁber struc-
ture, which oﬀers an ideal environment
for the migration of ﬁbroblasts and other
receptor cells, thereby contributing to
rapid integration and epithelialization
[1]. Pericardial patches are available in
a variety of sizes and are easy to store.
Thus, the additional preparatory tasks
required for the harvest of a venous graft
aredispensedwith. Bovinepatchcompli-
ance is similar to that of an autologous
artery, making it possible to achieve
reconstruction that closely resembles
the anatomical reality. This approach
minimizes the compliance mismatch
between wall and graft that contributes
to restenosis due to intimal hyperpla-
sia, particularly in endarterectomized
segments. Finally, bovine tissue is a
robust graft tissue without air inclusions,
thereby permitting prompt ultrasound
follow-up of the reconstructed area.
Infection rates also play an important
role in the selection of vascular replace-
ment materials. Compared with syn-
thetic patches, only a small number of
cases of patch infections have been pub-
lished for bovine pericardium [2]. This
factor, combined with the biophysical
characteristics of this particularmaterial,
prompted a number of working groups
to also use bovine patches in the setting
of infected grafts. This applies not only to
vascular surgery but also to other special-
ist surgical disciplines, such as thoracic
surgery (reconstruction of the trachea
and thoracic wall defects) [3] and car-
diac surgery (in combination with valve
repair procedures) [4].
The use of pericardial patches to re-
place the alloplastic patch infections seen
relatively frequently in the inguinal re-
gion has already been described. McMil-
lian et al. published a series of 51 patients
in whom PTFE patches in the inguinal
regionwerereplacedwithbovinepericar-
dial patches [5]. Although methicillin-
resistant Staphylococcus aureus (MRSA)
was detected in as many as 22% of the
infections, 50 of the patches remained
free of reinfection and did not require
revision surgery over a mean follow-up
of 2.1 years.
In the case of Szilagyi III inguinal in-
fections repaired using bovine patches,
the patch remains in place, unless bleed-
ing is present (Zülke-Harnoss grade III)
and treatment is carried out with de-
bridement, sartorius myoplasty, negative
pressure wound therapy (NPWT) and
antibiotic therapy.
Reconstruction using pericardial
tubes has also been described in aor-
tic graft infections and inﬂammatory
changes in the native aorta. As early as
1997, the working group led by Pirelli [6]
published ﬁve cases of infected infrarenal
grafts that were replaced in situ using
pericardial tubes [6]. In 2009 Motokawa
et al. reported on the replacement of
the thoracic aorta for an aortobronchial
ﬁstula [7] and the infrarenal aorta for a
mycotic aneurysm [8] using a custom-
made equine pericardial roll graft. Then,
in 2011, Schmidlis’ group [9] published
a series of 15 patients with graft in-
fections following open or endovascular
treatment, in whom grafts were removed
and replaced with pericardial tubes. Of
the patients 4 (27%) died while still
hospitalized due to the initial sepsis and
multiorgan failure. No cases of reinfec-
tion occurred during the 2-year follow-
up period. Similarly, no graft degrada-
tion or aneurysms were observed [9].
Bürger and Gebauer [10] provided an
excellent technical description of bovine
pericardial patches as bypass material in
the setting of infections. Large pericar-
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dial patches (10 ×15 cm or larger) are
sutured to form a tube using non-ab-
sorbable monoﬁlament suture material
(. Fig. 1). This can be performed free-
hand in the case of large lumen grafts
for aortic repair, while smaller lumen
interposition grafts can be sutured over
sterile cylinders of the appropriate diam-
eter (e.g. chest drainage tubes and Hegar
pins). Pericardial patches can be com-
bined with other graft materials, such as
biosynthetic grafts, veins or homografts
[11].
We also use the bovine pericardial
patch as graft material for localized in-
fection of plastic prostheses in shunt
surgery (. Fig. 2). Here, it is important
to place the suture lateral to the direction
of puncture in order to avoid damage
during shunt puncture and pseudoa-
neurysm formation. A healing time of
4–6 weeks should be allowed prior to
initial puncture.
Biosynthetic grafts
Biosynthetic grafts consist of a polyester
mesh enclosed in ovine collagen accord-
ing to the principle of a Sparks man-
dril graft. Once processed, involving in
particular ﬁxation with glutaraldehyde, a
stable collagen matrix forms. Due to the
low infection rates when used in shunt
surgery and elective bypass surgery as
well as the encouraging resultswithxeno-
geneic patches in the infected surgical
setting, eﬀorts have also beenmade in re-
cent years to evaluate biosynthetic grafts
as graft materials for infections. Initial
results on infected infrainguinal pros-
thetic grafts were published by our work-
ing group in 2012 [12] and by Fellmer
et al. in 2014 [13]. These investigations
showed that, in the absence of venous
material, it is possible to replace infected
inguinal grafts using Omniﬂow II® grafts
and achieve goods results. No reinfec-
tions were observed in the mean follow-
up period of 2 years. We recommend
using the Omniﬂow II® prosthesis for
femorocrural reconstruction due to its
lowerkink resistance; where possible, the
use of composite grafts with autologous
veins is preferred (. Fig. 3). In addition,
due to the initially higher thrombogenic-
ity, more intensive anticoagulation and
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Abstract
Background. In general, autologous veins
are the optimal replacementmaterial for an
infected vascular graft in terms of handling,
durability and resistance to reinfection. In
the absence of suitable autologous material,
several options are available, each of which
has speciﬁc advantages and drawbacks with
regard to these characteristics.
Methods. In recent years, xenogeneic
materials (in particular pericardial patches
from diﬀerent species and biosynthetic grafts)
have been increasingly used as replacement
material in the setting of infections. Bovine
and equine pericardial patches are applied
in particular as self-made tube grafts in
the aortic region and also in infections of
iliacofemoral prosthetic grafts and shunt
infections.
Results. The results of small clinical series on
durability and resistance to reinfection are
promising.
Conclusion. It is feasible to use biosynthetic
materials to replace infected intracavitary and
extracavitary vascular grafts with remarkably
low reinfection rates; however, the unique
mechanical properties of the grafts as well as
the initially increased thrombogenicity, need
to be taken into consideration.
Keywords
Infection · Vascular replacement · Xenogeneic
materials · Bovine patch · Omniﬂow
Xenogene Implantate in der septischen Gefäßchirurgie
Zusammenfassung
Hintergrund. Die autologe Vene stellt im
Allgemeinen das beste Ersatzmaterial für
eine inﬁzierte Gefäßprothese in Hinblick auf
Handling, Langlebigkeit und Infektresistenz
dar. Bei fehlendem autologem Material
stehen verschiedeneOptionen zur Verfügung,
deren Anwendung bezogen auf diese
Eigenschaften jeweils speziﬁsche Vor- und
Nachteile aufweist.
Methoden. In den letzten Jahren werden ver-
mehrt xenogene Materialien (insbesondere
Perikard-Patches verschiedener Spezies und
biosynthetische Prothesen) als Ersatzmaterial
in der Infektsituation verwendet. Bovine und
equine Patches kommen dabei insbesondere
als selbstgefertigte „tube grafts“ im aortalen
Bereich, aber auch bei Infektionen der
iliakofemoralen Strombahn oder bei
Shuntinfektionen zum Einsatz.
Ergebnisse. Die Ergebnisse kleiner Serien sind
in Bezug auf Langlebigkeit und Infektresistenz
sehr vielversprechend.
Schlussfolgerung. Die Anwendung
biosynthetischer Prothesen als Rekonstruk-
tionsmaterial bei intra- und extrakavitären
Protheseninfekten ist möglich, insbesondere
die Reinfektraten sind sehr niedrig. Allerdings
müssen bei der Implantation die besonderen
mechanischen Eigenschaften und die höhere
initiale Thrombogenität der Prothesen
beachtet werden.
Schlüsselwörter
Infektion · Gefäßersatz · Xenogene
Materialien · Boviner Patch · Omniﬂow
antiaggregation therapy is required, at
least until the healing process is com-
pleted.
InDecember2015Krasznai et al. pub-
lished a series of three patients with in-
fected aortic grafts that could be recon-
structed in situ using biosynthetic ma-
terial [14]. All infections were resolved.
We also use the Omniﬂow II® prosthesis
as replacement material for infected aor-
tobiiliac and aortobifemoral prosthetic
grafts (Töpel et al. International Surgical
Science [ISS] in press [to be published in
2016]), sometimes in combination with
other materials (. Fig. 4 and 5). There
were no cases of reinfection among our
patients, too.
Summary
Xenogeneic grafts have found broad ap-
plication in vascular surgery in the form
of pericardial patches. There is a growing
bodyof clinical data to suggest a rationale
for their use in the contaminated surgi-
cal ﬁeld or even as replacement material
for infected synthetic patches and grafts
in certain situations. Biosynthetic vascu-
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lar grafts are highly resistant to infection
when used in the elective setting; how-
ever, their use as replacement material
for infected infrainguinal vascular grafts
is only justiﬁed if autologous venousma-
terial is absent or insuﬃcient and if good
results have been seen in small applica-
tion studies. Their special mechanical
properties require particular considera-
tion, most notably in femorocrural ap-
plications. Initial experience with their
use in intracavitary graft infections has
been gained.
Conclusion
With careful preoperative evaluation and
patient selection, xenogeneic grafts rep-
resent a valuable treatment option in sep-
tic vascular surgery. The use of biosyn-
thetic grafts in particular is technically
challenging and follow-up requires ex-
perience and careful attention.
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